Reference Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

Ref Type
Authors Donald C. Porter, Mengqian Chen, Jiaxin Liang et al.
Title Targeting tumor microenvironment with selective small-molecule inhibitors of CDK8/19
Journal The Journal of Cancer Research
Abstract Text Cancer Res January 1, 2015 75; PR08


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Senexin B Senexin B 1 0
Drug Name Trade Name Synonyms Drug Classes Drug Description
Senexin B CDK8 Inhibitor 3 Senexin B is a protein kinase inhibitor of CDK8 and the CDK8 paralog, CDK19, which may result in tumor growth inhibition and enhance the effects of chemotherapeutic agents (Cancer Res January 1, 2015 75; PR08, PMID: 31717492, PMID: 28147342).
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown triple-receptor negative breast cancer not applicable Senexin B Preclinical - Cell line xenograft Actionable In a preclinical study, Senexin B prevented tumor growth and enhanced the effects of Adriamycin (doxorubicin) in cell line xenograft models of triple-receptor negative breast cancer (Cancer Res January 1, 2015 75; PR08). detail...